GLPwatch
Saxenda: Underlying Mechanisms and Clinical Outcomes
NCT02944500 · Active, not recruiting
Last updated 2026-05-28This clinical trial studies how Saxenda affects brain responses to food in adults with obesity.
Status Active, not recruiting Ongoing, but no longer enrolling new participants.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind study
Participants 28 people
Who can join Ages 18–100 · all sexes Healthy volunteers accepted.
Timeline Started 2016-11 · est. completion 2027-06
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT02944500 ↗
Description as written by the study sponsor.
The purpose of this protocol is to investigate the effect of treatment with the study drug Liraglutide, a GLP-1 receptor agonist, on centers of the brain that control appetite and food intake.
Treatments tested
- liraglutide also known as Saxenda Drug
- Placebo Other
| Main thing measured | BOLD response to food cues |
|---|---|
| Sponsor | Beth Israel Deaconess Medical Center |
| Conditions studied | Obesity |
| GLP-1 drugs | liraglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02944500 ↗